Revelation Biosciences Faces Delisting Concerns
Ticker: REVBW · Form: 8-K · Filed: Jan 7, 2025 · CIK: 1810560
| Field | Detail |
|---|---|
| Company | Revelation Biosciences, Inc. (REVBW) |
| Form Type | 8-K |
| Filed Date | Jan 7, 2025 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $12,075.00, $1.00 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
Related Tickers: REVB
TL;DR
REVB might get delisted, check the details.
AI Summary
Revelation Biosciences, Inc. filed an 8-K on January 7, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The company was formerly known as Petra Acquisition Inc. and changed its name on April 23, 2020. The filing also includes other events and financial statements.
Why It Matters
This filing indicates potential issues with Revelation Biosciences' continued listing on an exchange, which could impact its stock trading and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards suggests significant financial or operational distress for the company.
Key Players & Entities
- REVELATION BIOSCIENCES, INC. (company) — Registrant
- Petra Acquisition Inc. (company) — Former company name
- January 03, 2025 (date) — Earliest event date
- January 7, 2025 (date) — Filing date
FAQ
What specific listing rule or standard has Revelation Biosciences failed to satisfy?
The filing does not specify the exact rule or standard that has not been met, only that a notice has been issued.
What is the date of the earliest event reported in this 8-K filing?
The earliest event reported is dated January 03, 2025.
When did Revelation Biosciences change its name from Petra Acquisition Inc.?
The company changed its name from Petra Acquisition Inc. on April 23, 2020.
What is the company's primary industry classification?
The company's Standard Industrial Classification is Pharmaceutical Preparations [2834].
What is the filing date of this 8-K report?
This 8-K report was filed on January 7, 2025.
Filing Stats: 689 words · 3 min read · ~2 pages · Grade level 11.3 · Accepted 2025-01-07 16:05:18
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share REVB The Nasdaq Stock Mar
- $12,075.00 — of common stock at an exercise price of $12,075.00 per share REVBW The Nasdaq Stock Ma
- $1.00 — 2025 and its stock trading at or above $1.00 for at least ten consecutive trading da
Filing Documents
- revb-20250103.htm (8-K) — 47KB
- revb-ex99_1.htm (EX-99.1) — 19KB
- img220778470_0.jpg (GRAPHIC) — 18KB
- 0000950170-25-002828.txt ( ) — 244KB
- revb-20250103.xsd (EX-101.SCH) — 47KB
- revb-20250103_htm.xml (XML) — 7KB
01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 3, 2025, Revelation Biosciences, Inc. (the "Company") received a decision letter issued by the Nasdaq Hearings Panel granting the Company's request to continue its listing on The Nasdaq Stock Market, subject to effecting a reverse stock split by January 31, 2025 and its stock trading at or above $1.00 for at least ten consecutive trading days by February 14, 2025. The Company intends to file a subsequent Form 8-K to disclose the details of the reverse stock split, including the final split ratio, effective date, and any other material information, once such details are determined by the Board of Directors. Additionally, the Nasdaq Hearings Panel confirmed that the Company has regained compliance with the Stockholders' Equity Requirement of Listing Rule 5550(b)(1) for which, as previously disclosed, the Company received a notice of delisting on August 14, 2024.
01 Other Events
Item 8.01 Other Events. On January 6, 2025, the Company issued a press release titled "Nasdaq Grants Revelation Biosciences Inc. Continued Listing." A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in Item 8.01 and in Exhibit 99.1 will not be treated as "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated January 6, 2025 104 Cover Page Interactive Data File (embedded with the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. REVELATION BIOSCIENCES, INC. Date: January 7, 2025 By: /s/ Chester S. Zygmont, III Chester S. Zygmont, III Chief Financial Officer (principal financial and accounting officer)